Once you have made the decision to deploy ECP as your second-line therapy for steroid-refractory aGVHD or cGVHD, what practical considerations should clinicians be knowledgeable of when considering ECP treatment?

Once you have made the decision to deploy ECP as your second-line therapy for steroid-refractory aGVHD or cGVHD, what practical considerations should clinicians be knowledgeable of when considering ECP treatment?

Once you have made the decision to deploy ECP as your second-line therapy for steroid-refractory aGVHD or cGVHD, what practical considerations should clinicians be knowledgeable of when considering ECP treatment?

 


Created by

CMEducation Resources IQ&A Extracorporeal Photopheresis Intelligence Zone | The Multi-Specialty Perspective

Presenter

Daniel Couriel, MD, MS

Daniel Couriel, MD, MS

Daniel R. Couriel, MD, MS
Professor of Internal Medicine
Director, Huntsman Cancer Institute (HCI) Blood and Marrow Transplant Program
University of Utah School of Medicine
Salt Lake City, UT